Zimmer Biomet to Buy Pacira’s iovera Cold Therapy Device for $140M
ZBH•ZBH•ZBH•ZBH•Zimmer Biomet agreed to acquire Pacira’s iovera focused cold therapy device for $140 million, expanding its pain management portfolio. The iovera system delivers targeted nerve ablation via precision cold treatment, offering a non-opioid pain relief solution that could complement Zimmer’s orthopedic implants and strengthen recurring revenue streams.
Zimmer Biomet will acquire Pacira’s iovera focused cold therapy system for $140 million, securing rights to its intellectual property and existing inventory. Zimmer will integrate Pacira’s commercial footprint, assuming manufacturing, distribution, and customer support to drive broader market adoption.
The iovera device uses targeted nerve ablation via precision cold therapy to manage acute and chronic pain without opioids, potentially enhancing Zimmer Biomet’s procedural therapy offerings alongside its orthopedic implants. This acquisition aligns with Zimmer’s goal to diversify into high-margin, consumable-based therapies and strengthen recurring revenue streams.
